Enjoy complimentary customisation on priority with our Enterprise License!
The advanced drug delivery systems market share is expected to increase to USD 91.79 billion from 2021 to 2026, at a CAGR of 7.41%.
This advanced drug delivery systems market research report extensively covers advanced drug delivery systems market segmentation by type (oral, injection and inhalation, transdermal, carrier-based, and others) and geography (North America, Europe, Asia, and ROW). The advanced drug delivery systems market report also offers information on several market vendors, including 3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd. among others. Furthermore, this report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches.
Download the Free Report Sample to Unlock the Advanced Drug Delivery Systems Market Size for the Forecast Period and Other Important Statistics
Technavio categorizes the global advanced drug delivery systems market as a part of the global life sciences tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the advanced drug delivery systems market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the advanced drug delivery systems market encompasses successful business strategies deployed by the key vendors. The advanced drug delivery systems market is fragmented and the vendors are deploying growth strategies such as investment in R&D to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The advanced drug delivery systems market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
The rising chronic diseases is notably driving the advanced drug delivery systems market growth, although factors such as presence of stringent regulations may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the advanced drug delivery systems industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Advanced Drug Delivery Systems Market Driver
One of the key factors driving the global advanced drug delivery systems market growth is the rising chronic diseases. Unhealthy and sedentary lifestyle, increasing geriatric population, excessive saturated trans-fat food, tobacco abuse, high blood pressure, smoking, high cholesterol, diabetes, obesity, physical inactivity, and family history of CVD are risk factors for CVD. Prevalent cases of total CVD nearly doubled from 271 million in 1990 to 523 million in 2019. The number of CVD deaths steadily increased from 12.1 million in 1990, reaching 18.6 million in 2019. According to the CDC, in 2019, 28.2 million adults were diagnosed with heart disease in the US. Every year, 805,000 mortality cases are being recorded in the US due to heart disease, among which coronary heart disease (CHD) is the most common type of heart disease, with a mortality rate of approximately 360,900 in 2019. Thus, such factors are expected to drive the drug delivery system market during the forecast period.
Key Advanced Drug Delivery Systems Market Trend
Exponential spread of the COVID-19 infection is one of the key advanced drug delivery systems market trends that is expected to impact the industry positively in the forecast period. There is growing reliance on efficient drug delivery mechanisms to provide quick treatment for the disease in such dire circumstances. Moreover, the situation has generated several innovation opportunities for companies. For instance, in May 2020, UK-based Senzer Pharmaceuticals announced that it was working on creating inhalable targeted antivirals for COVID-19. Similar efforts are being made at the University of Texas at Austin, where an innovative inhaled formulation of niclosamide is being developed to treat COVID-19 symptoms. Such factors are projected to further support the market growth in the coming years.
Key Advanced Drug Delivery Systems Market Challenge
One of the key challenges to the global advanced drug delivery systems market growth is the presence of stringent regulations. Regulations are governed by state and foreign government agencies, such as the Food and Drug Administration (FDA) and the Center for Medicare Services of the US Department of Health and Human Services. The FDA's Center for Devices and Radiological Health (CDRH) regulate the development, testing, manufacturing, labeling, and marketing of medical devices in the US. Under the Federal Food, Drug, and Cosmetic Act (FFDCA) of 1938, medical devices are classified into Class I, Class II, and Class III depending on the degree of risk associated with the use of the device. In Europe, the European Medicines Agency (EMA) regulates medical devices under the European Union (EU) legislation 2017/745, which came into force in May 2017. Compliance with such stringent regulations is a potential challenge to the key players, which may hamper the market growth in the coming years
This advanced drug delivery systems market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Our report provides extensive information on the value chain analysis for the advanced drug delivery systems market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
44% of the market's growth will originate from North America during the forecast period. The US is the key market for advanced drug delivery systems in North America. Market growth in this region will be faster than the growth of the market in ROW.
The better adoption of improved drug delivery solutions and follow-up of advanced treatment approaches in healthcare in countries such as the US will facilitate the advanced drug delivery systems market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
To gain further insights on the market contribution of various segments Request for a FREE sample
The advanced drug delivery systems market share growth by the oral segment will be significant during the forecast period. The pharmaceutical companies, with simultaneous recognition of the therapeutic advantages of controlled drug delivery, are paying greater attention to the development and modification of oral release drug delivery systems, which will drive segment growth in the coming years.
This report provides an accurate prediction of the contribution of all the segments to the growth of the advanced drug delivery systems market size and actionable market insights on post COVID-19 impact on each segment.
|
Advanced Drug Delivery Systems Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Decelerate at a CAGR of 7.41% |
|
Market growth 2022-2026 |
$ 91.79 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
9.97 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 44% |
|
Key consumer countries |
US, UK, China, Germany, and France |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 6
*Exhibit 06: Key Finding 7
*Exhibit 07: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*Exhibit 08: Parent market
*Exhibit 09: Market Characteristics
**2.2 Value chain analysis
*Exhibit 10: Value chain analysis: Life Sciences Tools and Services
*2.2.1 Research and development
*2.2.2 Inputs
*2.2.3 Production
*2.2.4 Distribution
*2.2.5 Marketing and sales
*2.2.6 Post-sales and services
*2.2.7 Industry innovations
***3. Market Sizing
**3.1 Market definition
*Exhibit 11: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 12: Market segments
**3.3 Market size 2021
**3.4 Market outlook: Forecast for 2021 - 2026
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ billion)
*Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 15: Five forces analysis 2021 & 2026
**4.2 Bargaining power of buyers
*Exhibit 16: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 17: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 18: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 19: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 20: Threat of rivalry
**4.7 Market condition
*Exhibit 21: Market condition - Five forces 2021
***5. Market Segmentation by Type
**5.1 Market segments
*The segments covered in this chapter are:
*Exhibit 22: Type - Market share 2021-2026 (%)
**5.2 Comparison by Type
*Exhibit 23: Comparison by Type
**5.3 Oral - Market size and forecast 2021-2026
*Exhibit 24: Oral - Market size and forecast 2021-2026 ($ billion)
*Exhibit 25: Oral - Year-over-year growth 2021-2026 (%)
**5.4 Injection and inhalation - Market size and forecast 2021-2026
*Exhibit 26: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
*Exhibit 27: Injection and inhalation - Year-over-year growth 2021-2026 (%)
**5.5 Transdermal - Market size and forecast 2021-2026
*Exhibit 28: Transdermal - Market size and forecast 2021-2026 ($ billion)
*Exhibit 29: Transdermal - Year-over-year growth 2021-2026 (%)
**5.6 Carrier-based - Market size and forecast 2021-2026
*Exhibit 30: Carrier-based - Market size and forecast 2021-2026 ($ billion)
*Exhibit 31: Carrier-based - Year-over-year growth 2021-2026 (%)
**5.7 Others - Market size and forecast 2021-2026
*Exhibit 32: Others - Market size and forecast 2021-2026 ($ billion)
*Exhibit 33: Others - Year-over-year growth 2021-2026 (%)
**5.8 Market opportunity by Type
*Exhibit 34: Market opportunity by Type
***6. Customer landscape
**6.1 Overview
*Exhibit 35: Customer landscape
***7. Geographic Landscape
**7.1 Geographic segmentation
*The regions covered in the report are:
*Exhibit 36: Market share by geography 2021-2026 (%)
**7.2 Geographic comparison
*Exhibit 37: Geographic comparison
**7.3 North America - Market size and forecast 2021-2026
*Exhibit 38: North America - Market size and forecast 2021-2026 ($ billion)
*Exhibit 39: North America - Year-over-year growth 2021-2026 (%)
**7.4 Europe - Market size and forecast 2021-2026
*Exhibit 40: Europe - Market size and forecast 2021-2026 ($ billion)
*Exhibit 41: Europe - Year-over-year growth 2021-2026 (%)
**7.5 Asia - Market size and forecast 2021-2026
*Exhibit 42: Asia - Market size and forecast 2021-2026 ($ billion)
*Exhibit 43: Asia - Year-over-year growth 2021-2026 (%)
**7.6 ROW - Market size and forecast 2021-2026
*Exhibit 44: ROW - Market size and forecast 2021-2026 ($ billion)
*Exhibit 45: ROW - Year-over-year growth 2021-2026 (%)
**7.7 Key leading countries
*Exhibit 46: Key leading countries
**7.9 Market opportunity by geography
*Exhibit 47: Market opportunity by geography ($ billion)
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Rising chronic diseases
*8.1.2 Rising investment in research and development of drug delivery
*8.1.3 Rising healthcare expenditure globally
**8.2 Market challenges
*8.2.1 Presence of stringent regulations
*8.2.2 Poor healthcare infrastructure in underdeveloped or developing countries
*8.2.3 Biocompatibility and acceptability with human body
*Exhibit 48: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Covid-19 pandemic to create multiple opportunities in the market
*8.3.2 Introduction of targeted drug delivery system
*8.3.3 Reduced side effects
***9. Vendor Landscape
**9.1 Overview
*Exhibit 49: Vendor landscape
**9.2 Landscape disruption
*Exhibit 50: Landscape disruption
*Exhibit 51: Industry risks
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 52: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 53: Market positioning of vendors
**10.3 3M Co.
*Exhibit 54: 3M Co. - Overview
*Exhibit 55: 3M Co. - Business segments
*Exhibit 56: 3M Co. - Key offerings
*Exhibit 57: 3M Co. - Segment focus
**10.4 Alkermes Public Co. Ltd.
*Exhibit 58: Alkermes Public Co. Ltd. - Overview
*Exhibit 59: Alkermes Public Co. Ltd. - Business segments
*Exhibit 60: Alkermes Public Co. Ltd. - Key news
*Exhibit 61: Alkermes Public Co. Ltd. - Key offerings
**10.5 Antares Pharma Inc.
*Exhibit 62: Antares Pharma Inc. - Overview
*Exhibit 63: Antares Pharma Inc. - Business segments
*Exhibit 64: Antares Pharma Inc. - Key news
*Exhibit 65: Antares Pharma Inc. - Key offerings
**10.6 Baxter International Inc.
*Exhibit 66: Baxter International Inc. - Overview
*Exhibit 67: Baxter International Inc. - Business segments
*Exhibit 68: Baxter International Inc. - Key offerings
*Exhibit 69: Baxter International Inc. - Segment focus
**10.7 Becton Dickinson and Co.
*Exhibit 70: Becton Dickinson and Co. - Overview
*Exhibit 71: Becton Dickinson and Co. - Business segments
*Exhibit 72: Becton Dickinson and Co. - Key offerings
*Exhibit 73: Becton Dickinson and Co. - Segment focus
**10.8 Endo International Plc
*Exhibit 74: Endo International Plc - Overview
*Exhibit 75: Endo International Plc - Business segments
*Exhibit 76: Endo International Plc. - Key news
*Exhibit 77: Endo International Plc - Key offerings
*Exhibit 78: Endo International Plc - Segment focus
**10.9 NanoPass Technologies Ltd.
*Exhibit 79: NanoPass Technologies Ltd. - Overview
*Exhibit 80: NanoPass Technologies Ltd. - Product and service
*Exhibit 81: NanoPass Technologies Ltd. - Key offerings
**10.10 Nektar Therapeutics
*Exhibit 82: Nektar Therapeutics - Overview
*Exhibit 83: Nektar Therapeutics - Product and service
*Exhibit 84: Nektar Therapeutics - Key offerings
**10.11 Perrigo Co. Plc
*Exhibit 85: Perrigo Co. Plc - Overview
*Exhibit 86: Perrigo Co. Plc - Business segments
*Exhibit 87: Perrigo Co. Plc - Key offerings
*Exhibit 88: Perrigo Co. Plc - Segment focus
**10.12 Teva Pharmaceutical Industries Ltd.
*Exhibit 89: Teva Pharmaceutical Industries Ltd. - Overview
*Exhibit 90: Teva Pharmaceutical Industries Ltd. - Business segments
*Exhibit 91: Teva Pharmaceutical Industries Ltd. - Key offerings
*Exhibit 92: Teva Pharmaceutical Industries Ltd. - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 Objective
*11.1.3 Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 93: Currency conversion rates for US$
**11.3 Research Methodology
*Exhibit 94: Research Methodology
*Exhibit 95: Validation techniques employed for market sizing
*Exhibit 96: Information sources
**11.4 List of abbreviations
*Exhibit 97: List of abbreviations
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
